Lei Yang

TL;DR: In this paper, single-domain antibodies targeting BCMA, and chimeric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epitope CAR) comprising one or more anti-BCMA singledomain antibodies.

TL;DR: In this paper, pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator (such as immune checkpoint inhibitor) were provided, and methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy.

TL;DR: The generation of the first ALK-positive large B-cell lymphoma patient-derived xenograft model is reported, in which it is shown that next-generation ALK inhibitors are therapeutically active, and data support use of alectinib and lorlatinib as off-label therapeutic options for patients with relapsed or refractory ALK.

TL;DR: In this article, a novel chimeric antigen receptor and applications thereof were disclosed, wherein the novel CHA receptor comprises a signal peptide, an antigen binding domain, a transmembrane domain and an intracellular signal domain.